Tibet Rhodiola Pharmaceutical Holding Co. (SHA:600211)

Market Cap	12.25B
Revenue (ttm)	2.81B
Net Income (ttm)	1.01B
Shares Out	322.32M
EPS (ttm)	3.13
PE Ratio	12.14
Forward PE	n/a
Dividend	1.96 (5.15%)
Ex-Dividend Date	Apr 22, 2025

Volume	5,114,079
Average Volume	3,649,283
Open	38.00
Previous Close	38.00
Day's Range	36.85 - 38.12
52-Week Range	31.23 - 45.12
Beta	1.10
RSI	50.37
Earnings Date	Aug 14, 2025

About SHA:600211

Tibet Rhodiola Pharmaceutical Holding Co. produces and sells pharmaceuticals in China and internationally. The company offers biological products, tibetan medicine, chinese medicine, and chemical medicine products. It also offers capsules, preparations, granules, and coatings for cardiovascular, cerebrovascular, hepatobiliary, sprains and contusions, rheumatism, rheumatoid arthritis, colds, etc. Tibet Rhodiola Pharmaceutical Holding Co. was founded in 1999 and is based in Lhasa, China.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1999
• Employees: 596
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600211

Financial Performance

In 2024, SHA:600211's revenue was 2.81 billion, a decrease of -10.45% compared to the previous year's 3.13 billion. Earnings were 1.05 billion, an increase of 31.26%.